Thumbnail Image

Efficacy of agomelatine 25–50mg for the treatment of anxious symptoms and functional impairment in generalized anxiety disorder: A meta-analysis of three placebo-controlled studies

Stein, D.J.
Khoo, J-P.
Picarel-Blanchot, F.
Olivier, V.
Van Ameringen, M.
Introduction: The purpose of this study is to investigate the effects of agomelatine on anxious symptoms and functional impairment in a pooled dataset from randomized placebo-controlled trials for generalized anxiety disorder (GAD). Methods: Data from three randomized, placebo-controlled trials that evaluated the efficacy of agomelatine 25-50 mg were pooled. The short-term (12 weeks) efficacy of agomelatine was assessed in regards to (1) anxious symptoms using the Hamilton Anxiety Scale (HAM-A), and (2) functional impairment using the Sheehan Disability Scale (SDS). Meta-analysis using a random effect model was used to assess differences between groups. Remission and response rates for the HAM-A and SDS were calculated, and analyses were repeated in participants with more severe anxiety symptoms. Results: In total, 669 patients (340 on agomelatine; 329 on placebo) were included in the analyses. Compared to placebo, the agomelatine group had a significant reduction in HAM-A total score at week 12 (between group difference: 6.30 ± 2.51, p = 0.012). Significant effects were also found for symptom response on the HAM-A (67.1% of patients on agomelatine vs. 32.5% on placebo) and symptom remission (38.8% of patients on agomelatine vs. 17.3% on placebo). Compared to placebo, there was a significant difference in favour of the agomelatine group at week 12 on the SDS total score (5.11 ± 1.81, p = 0.005). Significant effects were also found for functional response on the SDS (79.1% of patients on agomelatine vs. 43.2% of placebo) and functional remission (55.2% of patients on agomelatine vs. 25.4% on placebo). All findings for anxious symptoms and functional impairment were confirmed in the subset of more severely anxious patients. Agomelatine was well tolerated by patients. Conclusion: This meta-analysis confirms that agomelatine reduces anxiety symptoms and improves the global functioning of GAD patients.
Journal Title
Journal ISSN
Volume Title
Springer Nature
Research Projects
Organizational Units
Journal Issue
Agomelatine,Functioning,Generalized anxiety disorder,Impairment,Meta-analysis,Neurology,Placebo,Short-term,SDG-03 Good health and wealth
Stein DJ, Khoo JP, Picarel-Blanchot F, Olivier V, Van Ameringen M. Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies. Adv Ther. 2021 Mar;38(3):1567-1583. doi: 10.1007/s12325-020-01583-9.
Embedded videos